基于肝功能保护的HAIC联合TACE方案对原发性肝癌长期疗效的评价

Evaluation of Long-term Efficacy of HAIC Combined with TACE Regimen for Primary Liver Cancer Based on Liver Function Protection

原文传递

导出

摘要目的:探讨基于肝功能保护的经肝动脉灌注化疗术(HAIC)联合经肝动脉插管化疗栓塞术(TACE)治疗原发性肝癌(HCC)的临床疗效及安全性。方法:回顾性分析上海杨思医院于2021年6月—2022年12月收治的80例HCC患者临床资料,按治疗方案将其分为对照组(使用TACE治疗)与观察组(使用HAIC+TACE治疗),各40例。比较两组近期疗效、T细胞亚群、不良反应及远期生存情况。结果:观察组客观有效率(ORR)高于对照组(P<0.05)。两组疾病控制率(DCR)对比,差异无统计学意义(P>0.05)。治疗后,相比于对照组,观察组CD3^(+)和CD4^(+)水平、CD4^(+)/CD8^(+)均更高(P<0.05)。两组不良反应总发生率对比,差异无统计学意义(P>0.05)。观察组死亡率低于对照组(P<0.05),中位总体生存期(OS)长于对照组(P<0.05)。结论:基于肝功能保护的TACE联合HAIC治疗HCC可获得良好的近期疗效,改善患者细胞免疫功能,延长其生存期,降低其死亡率,且安全性良好。 Objective:To investigate the clinical efficacy and safety of hepatic arterial infusion chemotherapy(HAIC)combined with transarterial chemoembolization(TACE)in the treatment of primary hepatocellular carcinoma(HCC).Methods:The clinical data of 80 HCC patients admitted to Shanghai Yangsi Hospital from June 2021 to December 2022 were retrospectively analyzed.According to the treatment regimen,they were divided into a control group(treated with TACE alone)and an observation group(treated with HAIC+TACE),with 40 cases in each group.The short-term efficacy,T-cell subsets,adverse reactions,and long-term survival were compared between the two groups.Results:The objective response rate(ORR)in the observation group was higher than that in the control group(P<0.05).There was no significant difference in the disease control rate(DCR)between the two groups(P>0.05).After treatment,the observation group showed higher levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)compared to the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The mortality rate in the observation group was lower than that in the control group,and the overall survival(OS)was longer(P<0.05).Conclusion:TACE combined with HAIC for HCC can achieve favorable short-term efficacy,improve cellular immune function,prolong survival,reduce mortality,and demonstrate good safety.

作者徐唯航刘秋桂杨海云叶璐萍 XU Weihang;LIU Qiugui;YANG Haiyun;YE Luping(Department of Pharmacy,Shanghai Yangsi Hospital,Shanghai 200126,China;Department of Hepatic Oncology,Shanghai Yangsi Hospital,Shanghai 200126,China)

机构地区上海杨思医院药剂科上海杨思医院肝肿瘤科

出处《延边大学医学学报》 2025年第9期105-107,共3页 Journal of Medical Science Yanbian University

关键词原发性肝癌经肝动脉灌注化疗术经肝动脉插管化疗栓塞术免疫功能 primary hepatocellular carcinoma hepatic arterial infusion chemotherapy transarterial chemoembolization immune function

分类号 R735.7 [医药卫生—肿瘤]